Sanofi India Ltd
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products.
- Market Cap ₹ 18,334 Cr.
- Current Price ₹ 7,961
- High / Low ₹ 9,380 / 6,138
- Stock P/E 30.9
- Book Value ₹ 441
- Dividend Yield 2.10 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 18.1 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
2,851 | |
2,044 | |
Operating Profit | 807 |
OPM % | 28% |
79 | |
Interest | 2 |
Depreciation | 40 |
Profit before tax | 846 |
Tax % | 29% |
603 | |
EPS in Rs | 261.78 |
Dividend Payout % | 64% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 1% |
1 Year: | 31% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
Equity Capital | 23 |
Reserves | 992 |
19 | |
681 | |
Total Liabilities | 1,715 |
315 | |
CWIP | 16 |
Investments | 0 |
1,384 | |
Total Assets | 1,715 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
230 | |
38 | |
-878 | |
Net Cash Flow | -610 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | |
---|---|
Debtor Days | 17 |
Inventory Days | 202 |
Days Payable | 89 |
Cash Conversion Cycle | 130 |
Working Capital Days | 25 |
ROCE % |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 17h
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
1d - Pronouncement by the Hon''ble National Company Law Tribunal, Mumbai bench, approving the Scheme of Arrangement ("Scheme") between Sanofi India Limited and Sanofi Consumer Healthcare India …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - The Company will hold an investor / analysts call on Financial Results for the Quarter ended 31st March 2024 on 16th May 2024 at 2:00 …
- Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 6 May
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 29 Apr
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT
-
May 2023Transcript PPT
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Mar 2021TranscriptNotesPPT
India - Branded generics (79% of CY20 revenues):[1] Top-7 brands contribute ~70% of domestic sales and are growing at high single digits.[2]